A specific threshold represents the point at which amyloid-driven tau pathology has been reduced below the threshold required to sustain neurodegeneration. However, the threshold is operationally undefined—the <0.15 pg/mL value lacks prospective validation and is likely derived from cross-sectional amyloid status cutoffs, not treatment cessation studies. The proposed pragmatic trial to validate this threshold has never been conducted and carries significant ethical and investment risk.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Testosterone/ANDROGEN RECEPTOR Axis Neuronal Androgen Binding"]
B["AR Nuclear Translocation Coactivator Recruitment and Hormonal Ligand"]
C["TM4SF5 and CD82 Expression Senescent Cell Surface Marker Induction"]
D["Senolytic Target Engagement p53-Dependent Apoptosis in SASP Cells"]
E["Inflammatory Niche Remodeling SASP Factor Clearance"]
F["Neurodegenerative Niche Improvement Reduced Inflammatory Tone"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#81c784,color:#81c784
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMIDValidation: 0%4 supporting / 3 opposing
✓For(4)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
2
4
1
MECH 2CLIN 4GENE 0EPID 1
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Longitudinal p-tau217 decline correlates with slow…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF patients with early Alzheimer's disease who cease anti-amyloid antibody therapy are stratified by baseline CSF p-tau217 (<0.15 pg/mL vs ≥0.15 pg/mL) and followed prospectively for 24 months post-cessation, THEN those with p-tau217 <0.15 pg/mL will demonstrate slower clinical progression (CDR-SB change <1.0 point) compared to those with p-tau217 ≥0.15 pg/mL.
pendingconf: 0.25
Expected outcome: Stratified clinical progression rate difference of ≥0.5 CDR-SB points favoring the <0.15 pg/mL group at 24 months post-cessation
Falsified by: No statistically significant difference (p>0.05) in CDR-SB progression between threshold-defined groups, or numerically worse outcomes in the <0.15 pg/mL group
Method: Pragmatic prospective cohort study enrolling 200+ participants from 3+ academic medical centers who stopped lecanemab, donanemab, or aducanumab, with CSF p-tau217 measured at cessation and clinical assessments at 6-month intervals through 24 months
IF ROC analysis is performed on CSF p-tau217 values from a treatment cessation cohort to empirically identify the optimal threshold for predicting durable clinical benefit (CDR-SB stability at 18-24 months), THEN the derived threshold will differ by ≥30% from the proposed <0.15 pg/mL value (i.e., be either <0.10 or >0.20 pg/mL).
Falsified by: The empirically derived threshold falls within ±10% of 0.15 pg/mL (i.e., 0.135-0.165 pg/mL range), indicating cross-sectional cutoffs were appropriate for cessation prediction
Method: Secondary analysis of existing anti-amyloid antibody trial datasets (e.g., TRAILBLAZER, CLARITY, ENGAGE) that captured CSF p-tau217 at treatment discontinuation and linked to post-cessation clinical outcomes
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
NA — Search for structure
Click to search RCSB PDB